Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Huamin Wang

Verified by OpenAlex author ID and NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5159119511; NIH RePORTER profile ID 8662829. Sources: funder_awards.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
5
Labs led
1
Collaborators
48
Papers, trials and grants by year

2007: 1 grant · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 1 grant · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 grant · 2021: 1 grant · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 grant · 2026: 1 paper

Papers 4

  1. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  2. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Last author DOI 10.3390/cancers15092608↗
  3. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-20-1484↗
  4. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cncr.25483↗

Grants 5

  1. Core C-Computational Core P01CA117969↗
  2. Clinical Significance of Pancreatic Cancer Differentiation and Dedifferentiation R01CA195651↗
  3. Novel Signaling Pathways Regulating Pancreatic Cancer Pathogenesis R01CA196941↗
  4. Proteasome-mediated Degradation of Hematopoietic Progenitor Kinase 1 in Pancreati R21CA149544↗
  5. Functional Study of Hematopoietic Progenitor Kinase-1 in Pancreatic Cancer AWARD pancan:2007-huamin-wang-md-phd-functional-study-of-hematopoietic-progen

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 2 shared papers, 1 shared grant, 2023–2026 · strength 0.79
  2. Raghu Kalluri · 1 shared paper, 1 shared grant, 2022–2025 · strength 0.57
  3. Keping Xie · 1 shared grant, 2021 · strength 0.56
  4. Cyril Henri Benes · 1 shared grant, 2025 · strength 0.45
  5. Gerald C Chu · 1 shared grant, 2025 · strength 0.45
  6. Phillip Andrew Futreal · 1 shared grant, 2025 · strength 0.45
  7. Ronald Anthony Depinho · 1 shared grant, 2025 · strength 0.45
  8. NABEEL El-BARDEESY · 1 shared grant, 2025 · strength 0.45
  9. Ralph Weissleder · 1 shared grant, 2025 · strength 0.45
  10. Lewis C. Cantley · 1 shared grant, 2025 · strength 0.45
  11. Sarah P. Thayer · 1 shared grant, 2025 · strength 0.45
  12. James wesley Horner · 1 shared grant, 2025 · strength 0.45
  13. Tyler Jacks · 1 shared grant, 2025 · strength 0.45
  14. Matthew H. G. Katz · 2 shared papers, 2023–2026 · strength 0.34
  15. Robert A. Wolff · 2 shared papers, 2023–2026 · strength 0.34
  16. Naruhiko Ikoma · 2 shared papers, 2023–2026 · strength 0.34
  17. Eugene Jon Koay · 2 shared papers, 2023–2026 · strength 0.34
  18. Michael James Overman · 1 shared paper, 2026 · strength 0.19
  19. Abdelrahman M.G. Yousef · 1 shared paper, 2026 · strength 0.19
  20. Jason A. Willis · 1 shared paper, 2026 · strength 0.19
  21. Saikat Chowdhury · 1 shared paper, 2026 · strength 0.19
  22. Ahmed Elhariri · 1 shared paper, 2026 · strength 0.19
  23. Mahmoud Yousef · 1 shared paper, 2026 · strength 0.19
  24. Haoqiang Ying · 1 shared paper, 2026 · strength 0.19
  25. Rebecca Anne Snyder · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.